Yukiko Miyamoto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9991468/publications.pdf

Version: 2024-02-01

43 papers 2,964 citations

304743 22 h-index 254184 43 g-index

44 all docs

44 docs citations

times ranked

44

4450 citing authors

#	Article	IF	CITATIONS
1	Olfactory receptor 2 in vascular macrophages drives atherosclerosis by NLRP3-dependent IL-1 production. Science, 2022, 375, 214-221.	12.6	81
2	Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice. Hepatology International, 2022, 16, 359-370.	4.2	15
3	Characterization of Metronidazole-Resistant Giardia intestinalis Lines by Comparative Transcriptomics and Proteomics. Frontiers in Microbiology, 2022, 13, 834008.	3.5	14
4	The fecal mycobiome in non-alcoholic fatty liver disease. Journal of Hepatology, 2022, 76, 788-799.	3.7	66
5	Codelivery of Antigens and Adjuvant in Polymeric Nanoparticles Coated With Native Parasite Membranes Induces Protective Mucosal Immunity Against <i>Giardia lamblia</i> Diseases, 2022, 226, 319-323.	4.0	8
6	Conserved metabolic enzymes as vaccine antigens for giardiasis. PLoS Neglected Tropical Diseases, 2022, 16, e0010323.	3.0	3
7	Deazapurine Nucleoside Analogues for the Treatment of <i>Trichomonas vaginalis</i> . ACS Infectious Diseases, 2021, 7, 1752-1764.	3.8	14
8	Gold(I) Phosphine Derivatives with Improved Selectivity as Topically Active Drug Leads to Overcome 5-Nitroheterocyclic Drug Resistance in <i>Trichomonas vaginalis</i>). Journal of Medicinal Chemistry, 2021, 64, 6608-6620.	6.4	7
9	Microbiota Modulates Cardiac Transcriptional Responses to Intermittent Hypoxia and Hypercapnia. Frontiers in Physiology, 2021, 12, 680275.	2.8	4
10	Comprehensive characterization of purine and pyrimidine transport activities in <i>Trichomonas vaginalis</i> and functional cloning of a trichomonad nucleoside transporter. Molecular Microbiology, 2021, 116, 1489-1511.	2.5	9
11	Click chemistry-facilitated comprehensive identification of proteins adducted by antimicrobial 5-nitroimidazoles for discovery of alternative drug targets against giardiasis. PLoS Neglected Tropical Diseases, 2020, 14, e0008224.	3.0	9
12	Composite Thermoresponsive Hydrogel with Auranofin‣oaded Nanoparticles for Topical Treatment of Vaginal Trichomonad Infection. Advanced Therapeutics, 2019, 2, 1900157.	3.2	19
13	20S Proteasome as a Drug Target in Trichomonas vaginalis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	16
14	Identification of Conserved Candidate Vaccine Antigens in the Surface Proteome of Giardia lamblia. Infection and Immunity, 2019, 87, .	2.2	21
15	Evaluation of Peroxides and Chlorine Oxides as Disinfectants for Chemical Sterilization of Gnotobiotic Rodent Isolators. Journal of the American Association for Laboratory Animal Science, 2019, 58, 558-568.	1.2	7
16	Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature, 2019, 575, 505-511.	27.8	493
17	Validation of Babesia proteasome as a drug target. International Journal for Parasitology: Drugs and Drug Resistance, 2018, 8, 394-402.	3.4	13
18	Neutralization of cholera toxin with nanoparticle decoys for treatment of cholera. PLoS Neglected Tropical Diseases, 2018, 12, e0006266.	3.0	19

#	Article	IF	CITATIONS
19	Click Chemistry-Facilitated Structural Diversification of Nitrothiazoles, Nitrofurans, and Nitropyrroles Enhances Antimicrobial Activity against Giardia lamblia. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	6
20	Skin microbiome promotes mast cell maturation by triggering stem cell factor production in keratinocytes. Journal of Allergy and Clinical Immunology, 2017, 139, 1205-1216.e6.	2.9	92
21	Microbiota and Alcoholic Liver Disease. Alcoholism: Clinical and Experimental Research, 2016, 40, 1791-1792.	2.4	8
22	Auranofin inactivates Trichomonas vaginalis thioredoxin reductase and is effective against trichomonads in vitro and in vivo. International Journal of Antimicrobial Agents, 2016, 48, 690-694.	2.5	32
23	Microbiota Protects Mice Against Acute Alcoholâ€Induced Liver Injury. Alcoholism: Clinical and Experimental Research, 2015, 39, 2313-2323.	2.4	92
24	Drug Development Against the Major Diarrhea-Causing Parasites of the Small Intestine, Cryptosporidium and Giardia. Frontiers in Microbiology, 2015, 6, 1208.	3.5	57
25	IL-17A promotes protective IgA responses and expression of other potential effectors against the lumen-dwelling enteric parasite Giardia. Experimental Parasitology, 2015, 156, 68-78.	1.2	70
26	Metronidazole-triazole conjugates: Activity against Clostridium difficile and parasites. European Journal of Medicinal Chemistry, 2015, 101, 96-102.	5 . 5	48
27	Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. FASEB Journal, 2015, 29, 1043-1055.	0.5	156
28	Hsp90 Inhibitors as New Leads To Target Parasitic Diarrheal Diseases. Antimicrobial Agents and Chemotherapy, 2014, 58, 4138-4144.	3.2	39
29	Expanded therapeutic potential in activity space of next-generation 5-nitroimidazole antimicrobials with broad structural diversity. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17564-17569.	7.1	57
30	A Reprofiled Drug, Auranofin, Is Effective against Metronidazole-Resistant Giardia lamblia. Antimicrobial Agents and Chemotherapy, 2013, 57, 2029-2035.	3.2	136
31	Impaired Parasite Attachment as Fitness Cost of Metronidazole Resistance in Giardia lamblia. Antimicrobial Agents and Chemotherapy, 2011, 55, 4643-4651.	3.2	59
32	Synthesis and Electrochemistry of 2-Ethenyl and 2-Ethanyl Derivatives of 5-Nitroimidazole and Antimicrobial Activity against <i>Giardia lamblia</i> . Journal of Medicinal Chemistry, 2009, 52, 4038-4053.	6.4	70
33	Subsidy system for purchasing hearing aids for moderately hearing-impaired children in Mie prefecture. Audiology Japan, 2008, 51, 279-285.	0.1	11
34	Role of Shiga toxin versus H7 flagellin in enterohaemorrhagic Escherichia coli signalling of human colon epithelium in vivo. Cellular Microbiology, 2006, 8, 869-879.	2.1	82
35	Deoxycholic acid formation in gnotobiotic mice associated with human intestinal bacteria. Lipids, 2006, 41, 835-843.	1.7	78
36	Epithelial Cell IÎB-Kinase Î2 Has an Important Protective Role in <i>Clostridium difficile</i> Toxin A-Induced Mucosal Injury. Journal of Immunology, 2006, 177, 1214-1220.	0.8	42

#	Article	IF	CITATIONS
37	Cathelicidin Mediates Innate Intestinal Defense against Colonization with Epithelial Adherent Bacterial Pathogens. Journal of Immunology, 2005, 174, 4901-4907.	0.8	205
38	Design of Speciesâ€Specific Primers to Identify 13 Species of <i>Clostridium</i> Harbored in Human Intestinal Tracts. Microbiology and Immunology, 2002, 46, 353-358.	1.4	69
39	Distribution Analysis of Six Predominant Bacteroides Species in Normal Human Feces Using 16S rDNA-Targeted Species-Specific Primers. Microbial Ecology in Health and Disease, 2002, 14, 133-136.	3.5	5
40	Development of 16S rRNA-Gene-Targeted Group-Specific Primers for the Detection and Identification of Predominant Bacteria in Human Feces. Applied and Environmental Microbiology, 2002, 68, 5445-5451.	3.1	576
41	Role of EHEC O157:H7 virulence factors in the activation of intestinal epithelial cell NF-κB and MAP kinase pathways and the upregulated expression of interleukin 8. Cellular Microbiology, 2002, 4, 635-648.	2.1	141
42	Comparison of Bacteriological, Genetic and Pathological Characters between Escherichia coli O115a,c:K(B) and Citrobacter rodentium Experimental Animals, 2001, 50, 183-186.	1.1	2
43	Design of cluster-specific 16S rDNA oligonucleotide probes to identify bacteria of theBacteroidessubgroup harbored in human feces. FEMS Microbiology Letters, 1999, 177, 143-149.	1.8	11